Vaccines work by controlled exposure to harmless whole-pathogens (viruses or bacteria) or specific antigens, which ensures that the immune system can adequately neutralize the pathogen when the organism is confronted with it.
There have been many technologies applied in vaccine development, including recombinant DNA technology (DNA vaccine, mRNA vaccine, recombinant subunit vaccine, VLP vaccine, etc.) and traditional non-recombinant technology (e.g., live attenuated vaccine, inactivated vaccine, polysaccharide vaccine, toxoid vaccine).
Based on our microbial expression systems (Escherichia coli, yeast), Yaohai Bio-Pharma offers Process and Manufacturing Solutions for recombinant vaccines against viruses, bacteria, cancer/tumors, and other diseases:
Technical Route
|
Yaohai‘s Business
|
Deliverables (intermediate/drug substance/drug product)
|
Services
|
mRNA vaccines
|
Yes
|
DS or DP: mRNA or LNP-mRNA
Our partner, NanoStar, licensed their own LNP patents to us.
|
Vaccines CRDMO services, including intermediates, drug substances (DS) or drug products (DP) 【GMP grade】
- Research samples preparation, such as mRNA, DNA or proteins;
- Microbial cell banking;
- Process development, such as fermentation, purification and formulation;
- Analysis method development;
- GMP manufacture of mRNA, DNA, and proteins;
- Quality control of the products;
- Regulatory affairs.
|
DNA vaccines
|
Yes
|
DS or DP: Plasmid DNA
|
Viral vector vaccines
|
Yes
|
Intermediate: Plasmid DNA
|
Subunit vaccines
|
Yes
|
DS or DP (adjuvant): recombinant antigens-based vaccines
e.g., Prophylactic vaccines for HPV, RSV, or therapeutic vaccines for cancer, and hypertension.
|
Protein/peptide-based therapeutic vaccines
|
Yes
|
Conjugate vaccines
|
Yes
|
DS or DP: Conjugate vaccines
e.g., Pneumococcal, meningococcal vaccines.
Intermediate: Carrier proteins
e.g., VLP, CRM197, tetanus toxin, etc.
|
Find more information on Vaccine Solutions in Yaohai Bio-Pharma.
|
Yaohai Bio-Pharma Offers One-Stop Solution for Recombinant Vaccine